List

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for the given year is not complete until April of the following year. Annual Reports data is a snapshot of agency reported information for that year and hence might look different from the live data in the Awards Information charts.

  1. Afterglow CsI(Tl) Scintillator for Medical Applications

    SBC: Radiation Monitoring Devices, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): CsI doped with thallium is one of the most important scintillators currently in use. In terms of conversion of ionizing radiation to visible photons, it is the unquestioned leader in efficiency. Additionally, its hi

    SBIR Phase II 2004 Department of Health and Human Services
  2. Pb-212 generator for cancer therapy

    SBC: ALPHAMED, INC            Topic: N/A

    DESCRIPTION (provided by applicant): The long-term objective of this proposal is to develop a lead-212/bismuth-212 (Pb-212/bi-212) generator and sufficient amounts of source material that will support clinical trials and approved drug products. The use o

    SBIR Phase I 2004 Department of Health and Human Services
  3. Molecular Test for Inherited Mutations in Breast Cancer

    SBC: AMBERGEN, INC            Topic: N/A

    DESCRIPTION (provided by applicant): Breast cancer is the most common malignancy, which occurs in women and the 2nd leading cause of cancer death. While the majority of breast cancers are sporadic (not inherited), approximately 10 percent are due to in

    SBIR Phase I 2004 Department of Health and Human Services
  4. Photocleavable ICAT Reagents for Quantitative Proteomics

    SBC: AMBERGEN, INC            Topic: N/A

    DESCRIPTION (provided by applicant): Proteomics is set to have a profound impact on disease diagnosis, treatment and monitoring. Protein expression profiling is one of the important parameters that can be monitored in the course of neoplastic disease.

    SBIR Phase I 2004 Department of Health and Human Services
  5. Mass Spectrometric Detection of Drug-Resistant HIV

    SBC: AMBERGEN, INC            Topic: N/A

    DESCRIPTION (provided by applicant): There are approximately one million persons in the U.S. infected with HIV-1, with 40,000 new cases reported each year. While most of these patients greatly benefit from highly active antiretroviral therapy (HAART), th

    SBIR Phase I 2004 Department of Health and Human Services
  6. Cell-Free Protein Labeling for Drug Discovery

    SBC: AMBERGEN, INC            Topic: N/A

    DESCRIPTION (provided by applicant): The human genome has opened a new chapter for drug discovery. In contrast to conventional drug discovery methods, which screen a drug library against a single protein target, the entire protein complement of the genome, i.e. the proteome, is now available for screening. A proteomic screen would greatly accelerate the drug discovery process by allowing potential ...

    SBIR Phase I 2004 Department of Health and Human Services
  7. Cell-Free Protein Labeling for Drug Discovery

    SBC: AMBERGEN, INC            Topic: N/A

    DESCRIPTION (provided by applicant): The human genome has opened a new chapter for drug discovery. In contrast to conventional drug discovery methods, which screen a drug library against a single protein target, the entire protein complement of the genome

    SBIR Phase II 2004 Department of Health and Human Services
  8. Microarray Assay for Detection of Lab Animal Pathogens

    SBC: AMBERGEN, INC            Topic: N/A

    DESCRIPTION (provided by applicant): The main goal of this project is to develop a microarray based system for comprehensive health assessment of laboratory animals. This microarray based test would be capable of simultaneous testing for the presence

    SBIR Phase I 2004 Department of Health and Human Services
  9. Synthesis and Optimization of a Malaria Vaccine

    SBC: ANCORA PHARMACEUTICALS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Plasmodium falciparum malaria infects 5-10% of the global population (400 million clinical cases) and kills two million people annually. As such it ranks along with HIV and TB as the most serious infectious disease of

    SBIR Phase I 2004 Department of Health and Human Services
  10. Synthesis & Characterization of a Tuberculosis Vaccine

    SBC: ANCORA PHARMACEUTICALS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Tuberculosis (TB) has plagued mankind for millennia. While several drugs and vaccine strategies have been developed to counter the TB, it remains a major infectious cause of morbidity and mortality worldwide. 1.Thoug

    SBIR Phase I 2004 Department of Health and Human Services

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government